ANDA 203613, held by Jubilant Generics. Levofloxacin.
As of Nov 16, 2026, ANDA 203613 (Levofloxacin), held by Jubilant Generics, was first approved by FDA on Jun 19, 2015, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 19, 2015 | Original application | Approved |
| Levofloxacin250MG · tablet;oral | Levofloxacin | Discontinued |
| Levofloxacin500MG · tablet;oral | Levofloxacin | Discontinued |
| Sep 20, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 16, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 16, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 19, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters